Cargando…
Risk factors of diffuse alveolar hemorrhage after acute ischemic stroke treated with tissue-type plasminogen activator. The effectiveness of activated recombinant factor VII treatment
BACKGROUND: Diffuse alveolar hemorrhage (DAH) is a rare and frequently life-threatening complication of a variety of conditions. DAH may result from coagulation disorders, inhaled toxins, or infections. We report a series of patients who developed DAH after receiving a tissue-type plasminogen activa...
Autores principales: | Shimizu, Yu, Tsuchiya, Katsuhiro, Fujisawa, Norihiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Scientific Scholar
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294161/ https://www.ncbi.nlm.nih.gov/pubmed/32547816 http://dx.doi.org/10.25259/SNI_2_2020 |
Ejemplares similares
-
Recombinant activated factor VII for diffuse alveolar hemorrhage in microscopic polyangiitis
por: Mandal, S. K., et al.
Publicado: (2012) -
Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage
por: Heslet, Lars, et al.
Publicado: (2006) -
Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic Vasculitis
por: Khoulani, Dania, et al.
Publicado: (2014) -
Treatment of diffuse alveolar hemorrhage secondary to lupus erythematosus with recombinant activated factor VII administered with a jet nebulizer
por: Esper, Raúl Carrillo, et al.
Publicado: (2014) -
Successful hemostasis in refractory alveolar hemorrhage using low-dose recombinant activated factor VII
por: Selickman, John, et al.
Publicado: (2022)